试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-29
Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients
编号:NCT04409886登记状态:提前终止企业 / 申办者:Maimonides Medical Center
药物 / 成分:Hyperbaric Oxygen Therapy
登记的停止原因(原文):This study is part of a larger national study. Only 1 patient was enrolled at Maimonides; Medical Center. The study was ended by the sponsor because the PI left; funding ended; , and no time, or personnel to do the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-28
Esmolol to Treat the Hemodynamic Effects of Septic Shock
编号:NCT02369900登记状态:提前终止企业 / 申办者:Beth Israel Deaconess Medical Center
药物 / 成分:Esmolol、Saline
登记的停止原因(原文):Funding expired, low enrollments
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-28
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
编号:NCT04762511登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Lower dose formulation of HSV vaccine (GSK4108771A)、Low dose formulation of HSV vaccine (GSK4108771A)、Medium dose formulation of HSV vaccine (GSK4108771A)、High dose formulation of HSV vaccine (GSK4108771A)
登记的停止原因(原文):To enable development of an enhanced version of the vaccine
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-25
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
编号:NCT01679080登记状态:提前终止企业 / 申办者:University of Aarhus
药物 / 成分:Zoledronic acid、Teriparatide、No active treatment
登记的停止原因(原文):Eli Lilly has withdrawn support to the study of teriparatide and placebo pens. The study was not able to continue as a randomized study without the supply of placebo pens.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-25
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
编号:NCT03386344登记状态:提前终止企业 / 申办者:Lexicon Pharmaceuticals
药物 / 成分:Sotagliflozin、Placebo
登记的停止原因(原文):Study terminated prematurely for financial reasons and Covid-19 pandemic.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-24
Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.
编号:NCT00223938登记状态:提前终止企业 / 申办者:Sanofi
药物 / 成分:Oral Iron、sodium ferric gluconate、sodium ferric gluconate
登记的停止原因(原文):The study was terminated because of significant enrollment challenges
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-24
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
编号:NCT00809354登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:NSAID、tanezumab、tanezumab、tanezumab
登记的停止原因(原文):See termination reason in detailed description.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-24
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
编号:NCT01486784登记状态:提前终止企业 / 申办者:Abramson Cancer Center at Penn Medicine
药物 / 成分:Birinapant
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-24
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
编号:NCT02417870登记状态:提前终止企业 / 申办者:Anil K. Chandraker, MD
药物 / 成分:aldesleukin
登记的停止原因(原文):lack of funding/resources
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-06-24
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
编号:NCT03577899登记状态:提前终止企业 / 申办者:Chengdu Kanghong Biotech Co., Ltd.
药物 / 成分:0.5 mg Conbercept Intravitreal Injection、1.0 mg Conbercept Intravitreal Injection、2.0 mg Aflibercept Intravitreal Injection
登记的停止原因(原文):desired primary endpoint was not met
查看官方原始记录 ↗